Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents

Biological Psychiatry

Volumn 57, Issue 3, 2005, Pages 261-267

  Griebel, Guy ^a   Stemmelin, Jeanne ^a   Scatton, Bernard ^a  

^a SANOFI   (France)

Author keywords

Animal models; anxiety; CB1 receptor; depression; rimonabant; rodents

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; DIAZEPAM; FLUOXETINE; RIMONABANT;

AGGRESSION; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; EMOTIONALITY; FLIGHT; FORCED SWIMMING TEST; GERBIL; INTERMETHOD COMPARISON; KNOCKOUT MOUSE; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RAT; RISK ASSESSMENT; STIMULUS; STRESS; TIME SERIES ANALYSIS; TONIC IMMOBILITY; TRANQUILIZING ACTIVITY;

AGGRESSION; ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BEHAVIOR, ANIMAL; DEPRESSION; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; EMOTIONS; FLUOXETINE; GERBILLINAE; IMMOBILITY RESPONSE, TONIC; MALE; MAZE LEARNING; MICE; MODELS, ANIMAL; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1;

EID: 13244253872     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2004.10.032     Document Type: Article

References (39)

1. B.E. Akinshola, A. Chakrabarti, E.S. Onaivi In-vitro and in-vivo action of cannabinoids Neurochem Res 24 1999 1233 1240
2. C. Arévalo, R. De Miguel, R. Hernandez-Tristan Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters Pharmacol Biochem Behav 70 2001 123 131
3. F. Chaperon, M.H. Thiébot Behavioral effects of cannabinoid agents in animals Crit Rev Neurobiol 13 1999 243 281
4. C.R. Cloninger Comorbidity of anxiety and depression J Clin Psychopharmacol 10 suppl 3 1990 43S 46S
5. C. Cohen, G. Perrault, C. Voltz, R. Steinberg, P. Soubrié SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats Behav Pharmacol 13 2002 451 463
6. G. Griebel, J.-L. Moreau, F. Jenck, J.R. Martin, R. Misslin Some critical determinants of the behaviour of rats in the elevated plus-maze Behav Process 29 1993 37 47
7. G. Griebel, D.J. Sanger, G. Perrault Genetic differences in the mouse defense test battery Aggress Behav 23 1997 19 31
8. G. Griebel, J. Simiand, R. Steinberg, M. Jung, D. Gully, P. Roger 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-me thylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor1 receptor antagonist. II. Characterization in rodent models of stress-related disorders J Pharmacol Exp Ther 301 2002 333 345
9. W. Hall, N. Solowij Adverse effects of cannabis Lancet 352 1998 1611 1616
10. J. Haller, N. Bakos, M. Szirmay, C. Ledent, T.F. Freund The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety Eur J Neurosci 16 2002 1395 1398
11. J. Haller, B. Varga, C. Ledent, I. Barna, T.F. Freund Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice Eur J Neurosci 19 2004 1906 1912
12. S. Hogg A review of the validity and variability of the elevated plus-maze as an animal model of anxiety Pharmacol Biochem Behav 54 1996 21 30
13. A. Holmes, J.P. Iles, S.J. Mayell, R.J. Rodgers Prior test experience compromises the anxiolytic efficacy of chlordiazepoxide in the mouse light/dark exploration test Behav Brain Res 122 2001 159 167
14. A. Holmes, R.J. Rodgers Responses of Swiss-Webster mice to repeated plus-maze experience Further evidence for a qualitative shift in emotional state? Pharmacol Biochem Behav 60 1998 473 488
15. A. Holmes, R.J. Rodgers Prior exposure to the elevated plus-maze sensitizes mice to the acute behavioral effects of fluoxetine and phenelzine Eur J Pharmacol 459 2003 221 230
16. L. Iversen High times for cannabis research Proc Natl Acad Sci U S A 96 1999 5338 5339
17. M. Maccarrone, O. Valverde, M.L. Barbaccia, A. Castane, R. Maldonado, C. Ledent Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice Correlation with behaviour Eur J Neurosci 15 2002 1178 1186
18. J. Manzanares, J. Corchero, J.A. Fuentes Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of Δ9-tetrahydrocannabinol in rats Brain Res 839 1999 173 179
19. M. Martin, C. Ledent, M. Parmentier, R. Maldonado, O. Valverde Involvement of CB1 cannabinoid receptors in emotional behaviour Psychopharmacology 159 2002 379 387
20. I.S. McGregor, F.N. Dastur, R.A. McLellan, R.E. Brown Cannabinoid modulation of rat pup ultrasonic vocalizations Eur J Pharmacol 313 1996 43 49
21. L.L. Murphy, R.M. Munoz, B.A. Adrian, M.A. Villanua Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion Neurobiol Dis 5 1998 432 446
22. M. Navarro, E. Hernandez, R.M. Munoz, I. delArco, M.A. Villanua, M.R.A. Carrera Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat Neuroreport 8 1997 491 496
23. E.S. Onaivi, M.R. Green, B.R. Martin Pharmacological characterization of cannabinoids in the elevated plus maze J Pharmacol Exp Ther 253 1990 1002 1009
24. S. Pellow, P. Chopin, S.E. File, M. Briley Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat J Neurosci Methods 14 1985 149 167
25. R.D. Porsolt, M. Le Pichon, M. Jalfre Depression A new animal model sensitive to antidepressant treatments Nature 266 1977 730 732
26. C. Ravinet-Trillou, M. Arnone, C. Delgorge, N. Gonalons, P. Keane, J.P. Maffrand Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice Am J Physiol Regul Integr Comp Physiol 284 2003 R345 R353
27. D. Robbe, M. Kopf, A. Remaury, J. Bockaert, O.J. Manzoni Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens Proc Natl Acad Sci U S A 99 2002 8384 8388
28. R.J. Rodgers, J. Haller, J. Halasz, E. Mikics "One-trial sensitization" to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze Eur J Neurosci 17 2003 1279 1286
29. F. Rodriguez de Fonseca, J.J. Fernandez Ruiz, L. Murphy, J.C. Eldridge, R.W. Steger, A. Bartke Effects of delta-9-tetrahydrocannabinol exposure on adrenal medullary function Evidence of an acute effect and development of tolerance in chronic treatments Pharmacol Biochem Behav 40 1991 593 598
30. F. Rodriguez de Fonseca, P. Rubio, F. Menzaghi, E. Merlo Pich, J. Rivier, G.F. Koob Corticotropin-releasing factor (CRF) antagonist [D-Phe12, Nle21,38, CaMeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats J Pharmacol Exp Ther 276 1996 56 64
31. F. Rodriguez de Fonseca, M.A. Villanua, R.M. Munoz, O. San-Martin-Clark, M. Navarro Differential effects of chronic treatment with either dopamine D1 or D2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid HU-210 in male rats Neuroendocrinology 61 1995 714 721
32. J. Simiand, J. Guitard, G. Griebel, P. Soubrié Tonic immobility in gerbils A new model for detecting antidepressant-like effects Behav Pharmacol 14 suppl 1 2003 S40
33. G. Tanda, E. Carboni, R. Frau, G. Di Chiara Increase of extracellular dopamine in the prefrontal cortex A trait of drugs with antidepressant potential Psychopharmacology 115 1994 285 288
34. D. Treit Animal models for the study of anti-anxiety agents A review Neurosci Biobehav Rev 9 1985 203 222
35. K. Tsou, S. Brown, M.C. Sanudo-Pena, K. Mackie, J.M. Walker Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system Neuroscience 83 1998 393 411
36. E.T. Tzavara, R.J. Davis, K.W. Perry, X. Li, C. Salhoff, F.P. Bymaster The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex Implications for therapeutic actions Br J Pharmacol 138 2003 544 553
37. J.R. Vogel, B. Beer, D.E. Clody A simple and reliable conflict procedure for testing anti-anxiety agents Psychopharmacologia 21 1971 1 7
38. P. Willner, R. Muscat, M. Papp Chronic mild stress-induced anhedonia A realistic animal model of depression Neurosci Biobehav Rev 16 1992 525 534
39. R.I. Wilson, R.A. Nicoll Endocannabinoid signaling in the brain Science 296 2002 678 682